Clinical Trial Update: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial assessing prexasertib in pediatric patients with recurrent or refractory solid tumors has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Solid Neoplasm
• Malignant Solid Neoplasm

Drugs mentioned

• Prexasertib (prexasertib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2023-12-20